Should You Buy, Sell, or Hold GE Healthcare Before Q2 Earnings?

GE HealthCare (GEHC) is poised to report Q2 2025 earnings, with consensus estimates projecting $4.97 billion in revenue (+2.8% YoY) and $0.91 EPS (-9% YoY), despite a history of beating estimates. While Q1 saw robust organic growth in Imaging and Pharmaceutical Diagnostics, the company anticipates a significant nearly $100 million headwind from tariffs in Q2, a key focus for investors alongside updates on new product launches like Flyrcado and the photon-counting CT system. The Zacks model does not conclusively predict an earnings beat for GEHC this quarter, indicating a mixed outlook.

Analysis

GE HealthCare (GEHC) faces a mixed outlook heading into its Q2 2025 earnings report. While consensus estimates project a 2.8% year-over-year revenue increase to $4.97 billion, earnings per share are expected to decline by 9% to $0.91. This anticipated profit contraction is primarily driven by a significant tariff-related headwind, which is forecast to impact earnings by nearly $100 million in the second quarter alone and drag down full-year adjusted EPS by approximately 85 cents. The company's segment performance highlights this divergence; strong Q1 organic growth and margin expansion were seen in the Imaging (+5% growth, +130 bps EBIT margin) and Pharmaceutical Diagnostics (+8% growth, >32% EBIT margin) divisions, which are expected to maintain momentum. Conversely, the Patient Care Solutions segment, despite 2% organic revenue growth, suffered a severe 450 basis point decline in its EBIT margin due to tariffs and an unfavorable product mix, indicating that margin pressure remains a critical issue. Although GEHC has a strong track record of beating earnings estimates, with an average surprise of 8.92% over the trailing four quarters, the Zacks model does not conclusively predict a beat this time, reflecting the material uncertainty posed by these cost pressures against the backdrop of long-term growth catalysts like the recent launch of the Flyrcado radiopharmaceutical and the planned regulatory submission for its photon-counting CT system.

Key Decisions for Investors

• Investors should scrutinize management's commentary on the Q2 earnings call for updates on tariff mitigation strategies, as progress here is critical to offsetting the expected 85-cent full-year EPS drag.
• Monitor the performance divergence between segments, paying close attention to any signs of margin stabilization in the tariff-impacted Patient Care Solutions division versus continued strength in the Imaging and Pharmaceutical Diagnostics units.
• Given the projected 9% YoY EPS decline and inconclusive earnings beat indicators, a cautious or neutral stance may be warranted until there is greater clarity on the duration of cost headwinds versus the commercial traction of new products like Flyrcado.
• Evaluate any updates on the innovation pipeline, particularly the regulatory timeline for the photon-counting CT system, as this remains a key long-term value driver that could influence sentiment beyond the immediate short-term earnings pressure.